2026-01-02 - Analysis Report
Okay, let's break down this JNJ (Johnson & Johnson) stock analysis.

**0) Report Structure**

First, I'll present the raw data points as requested. Then, I'll provide an analysis for each section, followed by a comprehensive summary at the end.

**1) Return Rate Comparison**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops, manufactures, and sells pharmaceuticals, medical devices, and consumer packaged goods.
*   **Cumulative Return (JNJ):** 52.50%
*   **Cumulative Return (VOO - S&P 500):** 105.07%
*   **Divergence:** -52.6 (Max: 7.1, Min: -74.8, Relative Divergence: 27.1)

**Analysis:**

*   JNJ has significantly underperformed the S&P 500 (VOO) over the period examined.
*   The divergence of -52.6% indicates a substantial difference in cumulative returns.  JNJ returned approximately half as much as the S&P 500.
*   The relative divergence of 27.1 suggests that the current divergence is closer to the minimum divergence observed historically within the given range (7.1 to -74.8).

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2016-2018  | 24.0%  | 10.1%  | -6.0%  | 0.7   | 310.9  |
| 2017-2019  | 29.0%  | 71.1%  | -13.0% | 0.7   | 351.4  |
| 2018-2020  | 14.0%  | 80.3%  | -19.0% | 0.7   | 379.2  |
| 2019-2021  | 29.0%  | 80.3%  | -47.0% | 0.6   | 412.2  |
| 2020-2022  | 19.0%  | 80.3%  | 0.0%   | 0.5   | 425.6  |
| 2021-2023  | -4.0%  | 79.5%  | -32.0% | 0.3   | 377.6  |
| 2022-2024  | -16.0% | 79.5%  | -46.0% | 0.2   | 348.4  |
| 2023-2025  | 27.0%  | 79.6%  | -41.0% | 0.1   | 498.6  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR fluctuates but generally shows decent growth historically, though the recent 2022-2024 period shows a negative rate.
*   **MDD (Maximum Drawdown):** High MDD figures suggest significant volatility and potential for large losses within those periods. The MDD values are all quite high (around 80%).
*   **Alpha:**  Negative Alpha values across most periods indicate that JNJ has underperformed relative to its risk-adjusted benchmark (likely the S&P 500, given the Beta analysis).
*   **Beta:**  Beta consistently below 1 suggests that JNJ is less volatile than the market.  The decreasing trend in Beta indicates a further reduction in volatility relative to the market over time.
*   **Cap(B) (Market Capitalization in Billions):** Shows the company's size and its progression over the years.

**2) Recent Stock Price Fluctuations**

*   **Close:** 206.95
*   **Last-Market:** {'price': 206.95, 'previousClose': 206.91, 'change': 0.02}
*   **5-day SMA:** 207.37
*   **20-day SMA:** 206.89
*   **60-day SMA:** 198.45

**Analysis:**

*   The closing price is nearly the same as the previous close, meaning it's roughly stable.
*   The 5-day SMA is slightly above the 20-day SMA, suggesting a slight upward trend in the very short term.
*   The 60-day SMA is significantly lower than both the 5-day and 20-day SMAs, indicating that the price has risen considerably over the past two months (60 days).

**3) RSI, PPO, and other indicators**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 50.90
*   **PPO:** -0.35
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.70)
*   **Recent (20 days) relative divergence change:** 3.2 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** 0.0

**Analysis:**

*   **MRI:** A value of 0.9 suggests a medium investment recommendation according to this indicator.
*   **RSI:**  An RSI around 50.90 indicates a neutral market. It's not overbought (above 70) or oversold (below 30).
*   **PPO:** A slightly negative PPO (-0.35) suggests a slightly weakening short-term trend relative to the longer-term trend.
*   **Hybrid Signal:** The hybrid signal suggests using 80% of available cash to buy, but expresses caution.
*   **Recent Divergence Change:** A positive divergence change suggests a recent improvement in JNJ's performance relative to its comparison.
*   **Expected Return:** An expected return of 0.0% is concerning and suggests no expectation of outperformance compared to the S&P 500 if invested long-term.

**4) Recent News & Significant Events**

*   **[2025-12-30] More Upside For JNJ Stock In 2026? - Forbes** - Suggests potential future growth for the stock.
*   **[2025-12-12] Is J&J’s 45.8% 2025 Surge Justified by Its Cash Flow and Earnings Outlook? - Yahoo Finance** - Questions the sustainability of recent gains based on financials.
*   **[2025-12-30] Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target - ts2.tech** -  Reports a stock slip following a deal closure, but a positive target price adjustment by Barclays.
*   **[2026-01-01] Johnson & Johnson $JNJ Shares Purchased by Ethic Inc. - MarketBeat** - Institutional buying indicates confidence from some investors.
*   **[2025-12-12] These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same? - The Motley Fool** - Further evidence of institutional interest.
*   **[2025-12-29] What To Expect From Johnson & Johnson Stock? - Trefis** - Suggests analysis and expectations for the stock's future performance.

**Analysis:**

The news is mixed, indicating a complex outlook:

*   Some articles suggest potential upside (Forbes, Trefis).
*   Others question the sustainability of recent gains (Yahoo Finance).
*   Institutional investment activity suggests confidence from some investors (MarketBeat, Motley Fool).
*   A deal closure resulted in a stock slip despite a target increase from Barclays (ts2.tech).

**4-2) Analyst Opinions**

*   **Consensus:** Buy (~2.16 on a scale of 1-5)
*   **Opinions:** 24 Analysts
*   **Target Price:** Avg: $210.13 / High: $240.00 / Low: $155.00
*   **Recent Rating Changes:** No Changes provided

**Analysis:**

*   The analyst consensus is "Buy," indicating generally positive sentiment.
*   The average target price ($210.13) is slightly above the current price ($206.95), suggesting a small potential upside. However, the range is wide ($155 - $240), indicating uncertainty.
*   A lack of recent rating changes makes it difficult to assess any shifting sentiment.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-22 | 2.14 | 23.99 B$  |
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2025-10-22 | 1.12 | 22.47 B$  |

**Analysis:**

*   The dates are slightly confusing as 2025-10-22 is listed twice; assuming the second instance is a typo, let's analyze.
*   EPS (Earnings Per Share) shows volatility. The $4.57 in 2025-04-23 is significantly higher than the other quarters. However, a repeat of 1.12 in 2024-10-23 and 2025-10-22.
*   Revenue (매출 - Sales) has been generally increasing over the past year, but not consistently.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $23.99B    | 69.56%        |
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |

**Analysis:**

*   Revenue has shown steady growth over the past year, peaking at $23.99B in the most recent quarter.
*   Profit margins are consistently high, above 66%, indicating good operational efficiency.

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-09-30   | $79.28B    | 6.50% |
| 2025-06-30   | $78.47B    | 7.06% |
| 2025-03-31   | $78.11B    | 14.08%|
| 2024-12-31   | $71.49B    | 4.80% |
| 2024-09-30   | $70.16B    | 3.84% |

**Analysis:**

*   Equity has increased steadily over the past year, reflecting the company's growth.
*   ROE (Return on Equity) is volatile, with a significant peak in Q1 2025.  The more recent ROEs are moderate.

**7) Comprehensive Analysis**

**Summary:**

Johnson & Johnson (JNJ) presents a mixed picture.  While the company is fundamentally strong with increasing revenue, high profit margins, and rising equity, it has significantly underperformed the S&P 500 in terms of cumulative return. The high MDD values associated with each year make it prone to high volatility.

**Key Considerations:**

*   **Underperformance:** The substantial divergence from the S&P 500 is a major concern for investors seeking market-level returns.
*   **Mixed Signals:** Technical indicators and analyst opinions are not strongly bullish or bearish. The MRI suggests a medium investment recommendation, but the expected return is 0.0%. Analyst consensus is "Buy" but is not a strong conviction.
*   **Volatile Earnings:** EPS and ROE volatility indicates potential uncertainty in future performance.
*   **Positive Financials:** The company's strong revenue growth and high profit margins are positives.
*   **Market Awareness:** Keep abreast of recent news. Monitor deal closures and impact to financials and price.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.